Skip to content
Alvimopan
Entereg (alvimopan) is a small molecule pharmaceutical. Alvimopan was first approved as Entereg on 2008-05-20. It is known to target mu-type opioid receptor, delta-type opioid receptor, and kappa-type opioid receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Entereg (generic drugs available since 2019-12-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alvimopan
Tradename
Company
Number
Date
Products
ENTEREGCubist PharmaceuticalsN-021775 RX2008-05-20
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
alvimopanANDA2023-04-26
enteregNew Drug Application2020-11-17
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Alvimopan, Entereg, Cubist Pharms
89462622030-02-12U-1655
ATC Codes
A: Alimentary tract and metabolism drugs
— A06: Drugs for constipation
— A06A: Drugs for constipation
— A06AH: Peripheral opioid receptor antagonists
— A06AH02: Alvimopan
HCPCS
No data
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiopulmonary bypassD002315———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35——1——1
ChickenpoxD002644EFO_0007204B01——1——1
Healthy volunteers/patients———1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell carcinoma of head and neckD00007719521———3
Myelodysplastic syndromesD009190D4611———2
Myeloid leukemia acuteD015470C92.011———2
Non-small-cell lung carcinomaD00228911———2
Prostatic neoplasmsD011471C6111———2
Kaposi sarcomaD012514C46—2———2
Myelomonocytic leukemia chronicD015477C93.1—1———1
Chemotherapy-induced febrile neutropeniaD064146—1———1
Urologic neoplasmsD014571C64-C68—1———1
Head and neck neoplasmsD006258—1———1
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B541———12
Urinary bladder neoplasmsD001749C672————2
Pancreatic neoplasmsD010190EFO_0003860C251————1
Gallbladder neoplasmsD005706EFO_0004606C231————1
Relapsing-remitting multiple sclerosisD020529EFO_00039291————1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01————1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003401————1
Philadelphia chromosomeD0106771————1
SarcomaD0125091————1
LymphomaD008223C85.91————1
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfertilityD007246EFO_0000545————22
Fertilization in vitroD005307————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameALVIMOPAN
INNalvimopan
Description
Alvimopan is a peptide.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
Identifiers
PDB—
CAS-ID156053-89-3
RxCUI1516803
ChEMBL IDCHEMBL270190
ChEBI ID—
PubChem CID5488548
DrugBankDB06274
UNII IDQ153V49P3Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
OPRM1
OPRM1
OPRD1
OPRD1
OPRK1
OPRK1
Organism
Homo sapiens
Gene name
OPRM1
Gene synonyms
MOR1
NCBI Gene ID
4988
Protein name
mu-type opioid receptor
Protein synonyms
hMOP, MOP, Mu opiate receptor, Mu opioid receptor, mu opioid receptor hMOR-1a
Uniprot ID
Q9UN57
Mouse ortholog
Oprm1 (18390)
mu-type opioid receptor (P42866)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 535 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alvimopan, Entereg
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15 adverse events reported
View more details